Sun Pharma sets October 30 results: 27 of 31 rate Sun Pharma stock Buy

Published on 10/19/2026 at 09:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q1 fiscal 2027 revenue reached INR 153.0 billion, up 10.5 percent year on year. Sun Pharma stock costs INR 1,742.70 at NSE on October 19, 2026 after INR 1,758.80.

Financial calendar and operating scale

Sun Pharma scheduled its second-quarter and half-year results for October 30, 2026.
Q1 fiscal 2027 revenue reached INR 153.0 billion, up 10.5 percent year on year.
Sun Pharma stock was at INR 1,742.70 on NSE on October 19, 2026 at 1:20 p.m. IST.

Sun Pharma, INE044A01036, Illustration mit AI erstellt.

Sun Pharma (ISIN INE044A01036) has scheduled its second-quarter and half-year fiscal 2027 results for October 30, 2026, according to The Economic Times. The company will report on the quarter ended September 30, while 27 of 31 tracked analysts carry a Buy or Strong Buy view, according to Sharpely on October 17, 2026.

October 30 results set the next test

The upcoming release matters because Sun Pharma enters the reporting date with a higher recent revenue base. Q1 fiscal 2027 revenue rose 10.5 percent year on year to INR 153.0 billion, while reported net profit increased 26.4 percent to INR 29.1 billion, according to DSIJ. The same report said EBITDA reached INR 41.8 billion and the EBITDA margin was 27.5 percent in the quarter.

Three dates frame the story

On July 31, 2026, Sun Pharma reported Q1 fiscal 2027 revenue of INR 153.0 billion. On October 12, 2026, the board approved a non-convertible debenture program of up to INR 100.0 billion, according to Stockfin. On October 15, 2026, the company announced the October 30 earnings call, according to The Economic Times.

What happens on October 30?

The board is scheduled to consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. The earnings call is also scheduled for October 30, 2026, giving investors a second reference point for management commentary on specialty medicines, domestic formulations and US generics.

Stock price and valuation context

Sun Pharma stock was at INR 1,742.70 on NSE on October 19, 2026 at 1:20 p.m. IST. The quote stood below the previous NSE close of INR 1,758.80, while the company had a market capitalization of INR 4.2 trillion and a 52-week range of INR 1,583.70 to INR 2,046.90 at the same market-data timestamp.